BioSpace News Archive

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the company’s three apoptosis-targeted drug candidates have been selected for presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced the launch of a new virtual care initiative with MediOrbis, a telehealth provider specializing in chronic conditions.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program using Psylocibin and Psilocin.

Sixty-nine-year-old Mark Eisen says he waited seven years for a surgery he hopes will change his life. Last week, he had the first total wrist replacement with KinematX™, a new implant co-designed by Scott W. Wolfe, MD, chief emeritus of the Hand and Upper Extremity Service at Hospital for Special Surgery.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its first quarter 2021 operating results on Wednesday, May 5, 2021 after market close, with a conference call to follow at 6:00 p.m. Eastern Time.

Lexington Medical, a US-based medical device company delivering minimally-invasive surgical stapling solutions, announced today that the company has achieved over 10,000 successful surgeries with the AEON™ Endostapler in multiple countries.

Formalization of the current relationship will allow PharmaDrug to expedite development timelines by leveraging SwRI’s existing Cepharanthine preclinical data sets and considerable manufacturing know-how.

The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).

Dr. John McGraw, President and CEO of Izotropic, commented, “I am extremely pleased to welcome Dr. Wu to our Advisory Board.